ADMA BIOLOGICS, INC. 8-K Analysis & Summary – 2/21/2025

⚠️This is not investment advice.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️

Filing date:

02/21/2025


TLDR:

ADMA Biologics, Inc. announced the Board’s approval of 2025 base salaries, 2024 cash bonuses, and annual incentive awards for key executives, as well as changes to director compensation.

ELI5:


Accession #:

0001140361-25-005489

Published on

Analyst Summary

  • Adam S. Grossman, President and CEO, received a $925,000 base salary, $1,020,000 cash bonus, 252,022 RSUs, and 376,744 stock options.
  • Kaitlin Kestenberg, COO, received a $575,000 base salary, $293,625 cash bonus, 77,784 RSUs, and 116,279 stock options.
  • Brad Tade, CFO, received a $500,000 base salary, $254,475 cash bonus, 62,227 RSUs, and 93,023 stock options.
  • Non-employee directors will receive annual equity grants equal to $350,000 of long-term incentive value, split 50% RSUs and 50% stock options.
  • Committee chair retainers increased to $25,000 for Audit, $20,000 for Compensation, and $12,500 for Governance and Nominations.
  • Committee member retainers increased to $12,500 for Audit, $10,000 for Compensation, and $6,250 for Governance and Nominations.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️